An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the U.S. for Patients with Stage 3 Type 1 Diabetes On June 13, Sanofi announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in endogenous (own)...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in CAH at ENDO 2026 On June 14, Crinetics Pharmaceuticals, Inc. presented data from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent Trial On May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Lilly’s Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial On May 21, Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution On May 13, Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Viridian Therapeutics Sees Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease On May 5, Viridian Therapeutics, Inc., announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Shows Promise in Phase 3 Trial On April 28, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years...
